KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-Current Assets (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Non-Current Assets data on record, last reported at $771.1 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 15.68% year-over-year to $771.1 million; the TTM value through Sep 2025 reached $3.7 billion, up 19.89%, while the annual FY2024 figure was $889.7 million, 29.84% up from the prior year.
  • Non-Current Assets reached $771.1 million in Q3 2025 per SRPT's latest filing, down from $1.0 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.0 billion in Q1 2025 and bottomed at $476.9 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $676.9 million, with a median of $653.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 38.81% in 2024, then fell 15.68% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $543.9 million in 2021, then grew by 4.9% to $570.5 million in 2022, then increased by 20.11% to $685.2 million in 2023, then rose by 29.84% to $889.7 million in 2024, then fell by 13.33% to $771.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $771.1 million in Q3 2025, $1.0 billion in Q2 2025, and $1.0 billion in Q1 2025.